Fujian Shengdi Pharmaceutical Co., Ltd.

This study tests an investigational injection called HRS9531 in 200 obese adults with a type of heart failure (preserved ejection fraction). Participants receive either the drug or a placebo weekly for 52 weeks. The goal is to see if the drug improves heart failure symptoms and h…

This study tests a new drug called HRS9531 against a standard weight-loss drug, semaglutide, in adults with obesity. About 572 people will receive weekly injections for 52 weeks to see which drug leads to more weight loss and better health measures like waist size. The goal is to…

This study tests an experimental drug called HRS-5632 in about 200 adults who have high levels of lipoprotein(a), a fatty substance in the blood that raises the risk of heart attacks and strokes. Participants receive either the drug or a placebo to see if the drug safely lowers t…